NCT02971995

Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies

Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies in Prostate Cancer Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Lille Catholic University · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection). The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .

Conditions

• Prostatic Neoplasm
• Positron-Emission Tomography
• Fluorocholine

Interventions

Type	Name	Description
DEVICE	PET Scan ou TEP-TDM	Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
DEVICE	mpMRI	Performance of the mpMRI in order to determine the place where to take the biopsy

Timeline

• Start date: 2014-12-01
• Primary completion: 2016-03-01
• Completion: 2016-10-01
• First posted: 2016-11-23
• Last updated: 2016-11-23